Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Consumer,Meningococcal group B vaccine - Invasive meningococcal disease,All adolescents 13-25 years,Meningococcal group B vaccine - Invasive meningococcal disease (Bexsero),Recommended for decline,,
